SecBot SecBot
SECBOTREPLAY Home › Report › PVLA

PVLA · Palvella Therapeutics announced that its Chief Scientific Officer, Dr

Palvella Therapeutics Inc. · PRESS-RELEASE filed Jul 30, 2026 at 07:30 ET

At the news

NEUTRALIMPACT 2/10

PRESS-RELEASE filed Jul 30, 2026 at 07:30 ET

Palvella Therapeutics announced that its Chief Scientific Officer, Dr. Jeffrey Martini, has been selected to provide public comment at an FDA public meeting on drug repurposing on August 5, 2026. This is a routine speaking engagement with no financial or regulatory impact on the company's pipeline or stock.

  • Dr. Martini will provide public comment at an FDA public meeting on drug repurposing on August 5, 2026.
  • The meeting is convened by the Reagan-Udall Foundation in collaboration with the FDA.
  • No financial data, clinical results, or regulatory decisions were announced.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access